GI
CPRX

GAMMA Investing’s Catalyst Pharmaceutical CPRX Stock Holding History

GAMMA Investing’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
4,150
+639
+18% +$18.9K ﹤0.01% 1607
2026
Q1 		$86.9K Buy
3,511
+944
+37% +$22.5K ﹤0.01% 1789
2025
Q4 		$59.9K Sell
2,567
-40
-2% -$891 ﹤0.01% 1950
2025
Q3 		$51.4K Sell
2,607
-569
-18% -$11.7K ﹤0.01% 1971
2025
Q2 		$68.9K Buy
3,176
+385
+14% +$9.09K ﹤0.01% 1697
2025
Q1 		$67.7K Buy
2,791
+579
+26% +$13K 0.01% 1566
2024
Q4 		$46.2K Buy
2,212
+434
+24% +$9.32K ﹤0.01% 1718
2024
Q3 		$35.3K Buy
1,778
+681
+62% +$12.6K ﹤0.01% 1734
2024
Q2 		$17K Sell
1,097
-845
-44% -$13.2K ﹤0.01% 1959
2024
Q1 		$31K Buy
1,942
+819
+73% +$12.3K 0.01% 1345
2023
Q4 		$16.2K Buy
+1,123
New +$15.4K ﹤0.01% 1632

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

GAMMA Investing's CPRX Position: Q2 2026 in Review

GAMMA Investing increased its Catalyst Pharmaceutical (CPRX) stake by 18% in Q2 2026, buying an estimated $18.9K and bringing the position to 4,150 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

GAMMA Investing first reported a position in CPRX in Q4 2023 and has held it in 11 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • GAMMA Investing held 4,150 shares of Catalyst Pharmaceutical worth $130K as of Q2 2026.
  • GAMMA Investing bought 639 Catalyst Pharmaceutical shares in Q2 2026, an estimated $18.9K.
  • Catalyst Pharmaceutical made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #1607 holding.
  • GAMMA Investing first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.